These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31292400)

  • 1. Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan.
    Iwasa M; Ishihara T; Kato M; Isoai A; Kobayashi R; Torii N; Soneda N; Takei Y
    Intern Med; 2019 Nov; 58(21):3069-3075. PubMed ID: 31292400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results.
    Hanafusa N; Isoai A; Ishihara T; Inoue T; Ishitani K; Utsugisawa T; Yamaka T; Ito T; Sugiyama H; Arakawa A; Yamada Y; Itano Y; Onodera H; Kobayashi R; Torii N; Numata T; Kashiwabara T; Matsuno Y; Kato M
    PLoS One; 2017; 12(5):e0177303. PubMed ID: 28510606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.
    Zhang X; Wang SZ; Zheng JF; Zhao WM; Li P; Fan CL; Li B; Dong PL; Li L; Ding HG
    World J Gastroenterol; 2014 Aug; 20(32):11400-5. PubMed ID: 25170228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.
    Chishina H; Hagiwara S; Nishida N; Ueshima K; Sakurai T; Ida H; Minami Y; Takita M; Kono M; Minami T; Iwanishi M; Umehara Y; Watanabe T; Komeda Y; Arizumi T; Kudo M
    Dig Dis; 2016; 34(6):659-664. PubMed ID: 27750234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study.
    Uojima H; Hidaka H; Nakayama T; Sung JH; Ichita C; Tokoro S; Masuda S; Sasaki A; Koizumi K; Egashira H; Kako M
    World J Gastroenterol; 2017 Dec; 23(45):8062-8072. PubMed ID: 29259382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites.
    Goto A; Terai S; Nakamura M; Matsumoto M; Sakaida I
    Clin J Gastroenterol; 2015 Feb; 8(1):47-51. PubMed ID: 25475138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy against cirrhotic ascites in comparison with malignancy-related ascites.
    Ito T; Hanafusa N; Soneda N; Isoai A; Kobayashi R; Torii N; Kato M
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3224-3232. PubMed ID: 34250635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.
    Namba M; Hiramatsu A; Aikata H; Kodama K; Uchikawa S; Ohya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Kawaoka T; Tsuge M; Imamura M; Chayama K
    J Gastroenterol; 2020 Feb; 55(2):217-226. PubMed ID: 31485782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cases with Refractory Ascites and a Delayed Response to Tolvaptan.
    Hagiwara S; Nishida N; Chishina H; Ida H; Sakurai T; Komeda Y; Kitano M; Kudo M
    Intern Med; 2016; 55(22):3273-3277. PubMed ID: 27853068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of ascites in cirrhotic patients].
    Kurosaki M; Nakanishi H; Izumi N
    Nihon Shokakibyo Gakkai Zasshi; 2017; 114(1):27-34. PubMed ID: 28070092
    [No Abstract]   [Full Text] [Related]  

  • 11. Changes in Coagulation and Fibrinolytic Factors in Patients With Cirrhotic Refractory Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy: A Retrospective Observational Study in Japan.
    Yorioka N; Namisaki T; Shibamoto A; Suzuki J; Kubo T; Iwai S; Tomooka F; Tanaka M; Takeda S; Fujimoto Y; Enomoto M; Muarata K; Inoue T; Tsuji Y; Fujinaga Y; Nishimura N; Kitagawa K; Takaya H; Kaji K; Kawaratani H; Akahane T; Mitoro A; Yamazaki M; Yoshiji H
    In Vivo; 2023; 37(3):1226-1235. PubMed ID: 37103093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Tajiri K; Tokimitsu Y; Ito H; Atarashi Y; Kawai K; Minemura M; Yasumura S; Takahara T; Shimizu Y; Sugiyama T
    Dig Dis; 2018; 36(4):314-321. PubMed ID: 29852495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New therapeutic paradigm and concepts for patients with cirrhotic refractory ascites].
    Wang SZ; Ding HG
    Zhonghua Gan Zang Bing Za Zhi; 2017 Apr; 25(4):249-253. PubMed ID: 28494541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma concentration and efficacy of tolvaptan in cirrhotic patients with refractory ascites.
    Sagawa E; Okubo H; Ando H; Sorin Y; Kanazawa R; Nakadera E; Fukada H; Kokubu S; Miyazaki A
    J Pharmacol Sci; 2019 Apr; 139(4):373-376. PubMed ID: 30857764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endotoxin Activity Reflects an Increase in Body Temperature in Cirrhotic Patients With Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy.
    Namisaki T; Tsuji Y; Kitade M; Yorioka N; Fujinaga Y; Sawada Y; Nishimura N; Kitagawa K; Inoue T; Takaya H; Kaji K; Kawaratani H; Moriya K; Akahane T; Mitoro A; Yoshiji H
    In Vivo; 2022; 36(3):1477-1484. PubMed ID: 35478114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study).
    Sakaida I; Terai S; Kurosaki M; Okada M; Hirano T; Fukuta Y
    J Gastroenterol; 2020 Aug; 55(8):800-810. PubMed ID: 32388692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study.
    Shiba S; Chu PS; Nakamoto N; Yamataka K; Taniki N; Ojiro K; Yamaguchi A; Morikawa R; Yoshida A; Ikura A; Ebinuma H; Saito H; Kanai T
    BMC Gastroenterol; 2020 Mar; 20(1):53. PubMed ID: 32138675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.
    Miyazaki M; Yada M; Tanaka K; Senjyu T; Goya T; Motomura K; Kohjima M; Kato M; Masumoto A; Kotoh K
    World J Gastroenterol; 2017 Aug; 23(29):5379-5385. PubMed ID: 28839438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites.
    Hiramine Y; Uto H; Mawatari S; Kanmura S; Imamura Y; Hiwaki T; Saishoji A; Oku M; Tokushige K; Maenohara S; Ido A
    J Gastroenterol; 2021 Jan; 56(1):54-66. PubMed ID: 32959093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effects of diuretics and paracentesis on lung function in patients with non-alcoholic cirrhosis and tense ascites.
    Chang SC; Chang HI; Chen FJ; Shiao GM; Wang SS; Lee SD
    J Hepatol; 1997 Apr; 26(4):833-8. PubMed ID: 9126796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.